In the same line, Evans et al. demonstrated that SEMA4D expression at the invasive tumor edge creates a barrier to immune infiltration, while antibody-mediated neutralization of SEMA4D could restore the immune response in the TME of murine models of colon cancer and an ERBB2+ mammary carcinoma [24]. This evidence concerns the gene SEMA4D and breast carcinoma.